Ensysce Biosciences Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Ensysce Biosciences Inc 's ROA in the first quarter of 2026?
Ensysce Biosciences Inc recorded a cumulative net loss of $-12 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -256.6%.

However, within the Healthcare sector 877 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4537, from total ROA ranking in the fourth quarter of 2025 at 5176.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	-52.99 %	33.15 %	-85.99 %	99.4 %	-9.11 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-12	-10	-11	-7	-7
Return On Assets (TTM)	-256.6 %	-195.52 %	-231.45 %	-68.41 %	-76.36 %
ENSC's Total Ranking	# 4537	# 5176	# 4637	# 4470	# 4605
Total Assets (TTM) in million	2	7	3	6	5
Seq. Total Assets Change	-70.91 %	134.4 %	-42.96 %	20.87 %	-17.6 %
Seq. Net Income Change	-	-	-	-	-

ENSC's 5 Years Annual ROA >> Back to ENSC Management Effectiveness >> Compare ENSC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 420
Sector	# 878
Overall	# 4488

Return On Assets Statistics
High	Average	Low
-0.61 %	-180.61 %	-390.93 %
(Jun 30 2021)		(Mar 31 2023)

Financial Statements
Ensysce Biosciences Inc 's Assets	$ 2 million	ENSC's Balance sheet
Ensysce Biosciences Inc 's Income	$ -4 million	Quarterly ENSC's Income Statement
ENSC's Income by Division		See ENSC's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	33.15 %	106.69 %	-53.98 %	-64.15 %	-91.98 %
Total Assets in million	7	6	3	6	16
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-10	-8	-11	-24	-29
Annual Return On Assets	-136.55 %	-142.7 %	-392.4 %	-411.34 %	-177.53 %

ENSC's 5 Years Annual ROA >> Back to ENSC Management Effectiveness >> Compare ENSC ROA to its Competitors

More Return On Assets Ratios
ENSC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ENSC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ENSC's Competitors
Subscribers only: Roa for Ensysce Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for ENSC's Customers

You may also want to know
ENSC's Roi	ENSC's Inventory Turnover Ratio	ENSC's Growth Rates	ENSC's Dividend Comparisons
	ENSC's Profitability Ratios	ENSC's Asset Turnover Ratio	ENSC's Dividend Growth
ENSC's Roe	ENSC's Valuation Ratios	ENSC's Financial Strength Ratios	ENSC's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.